ninlaro 3 mg hard capsule capsule, hard
takeda pharma a/s, denmark - ixazomib citrate - capsule, hard - 3 mg
ninlaro 2.3 mg
takeda israel ltd - ixazomib as citrate - capsules - ixazomib as citrate 2.3 mg - ixazomib - ninlaro is indicated, in combination with lenalidomide and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.
ninlaro 2.3 mg
takeda israel ltd - ixazomib as citrate - capsules - ixazomib as citrate 2.3 mg - ixazomib - ninlaro is indicated, in combination with lenalidomide and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.
ninlaro 4mg capsules
takeda uk ltd - ixazomib citrate - capsule - 4mg
ninlaro ixazomib (as citrate) 4mg capsule blister pack
takeda pharmaceuticals australia pty ltd - ixazomib citrate, quantity: 5.7 mg (equivalent: ixazomib, qty 4 mg) - capsule - excipient ingredients: microcrystalline cellulose; purified talc; magnesium stearate; gelatin; titanium dioxide; iron oxide yellow; iron oxide red; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; purified water; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - ninlaro is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy.
ninlaro 2.3 mg hard capsule capsule, hard
takeda pharma a/s, denmark - ixazomib citrate - capsule, hard - 2.3 mg
ninlaro 2.3 mg hard capsule capsule, hard
takeda pharma a/s, denmark - ixazomib citrate - capsule, hard - 2.3 mg
ninlaro 4 mg hard capsule capsule, hard
takeda pharma a/s, denmark - ixazomib citrate - capsule, hard - 4 mg
ninlaro 4 mg hard capsule capsule, hard
takeda pharma a/s, denmark - ixazomib citrate - capsule, hard - 4 mg
ninlaro 4 mg
takeda israel ltd - ixazomib as citrate - capsules - ixazomib as citrate 4 mg - ixazomib - ninlaro is indicated, in combination with lenalidomide and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.